Towards an assessment of toxicity in the treatment of ovarian cancer
Using data from a randomised clinical trial of two platinum drugs at The Royal Marsden Hospital, London, a descriptive model of toxicity has been developed and tested. Toxicity manifests itself in reducing the effectiveness of different body processes; five were selected in this study as being most critical. The model summarises and combines data from these five sites in terms of a clinician's assessment of the associated risk to the patient. It is hoped that the approach will help clarify toxicity information for use in patient management decision-making and in the reporting of clinical trial results.
KeywordsClinical Trial Platinum Ovarian Cancer Cancer Research Patient Management
Unable to display preview. Download preview PDF.
- 1.Keeney RL, Raiffa H (1976) Decisions with multiple objectives: preferences and value trade-offs. Wiley, New YorkGoogle Scholar
- 2.Pocock SJ (1983) Clinical trials. A practical approach. Wiley, New YorkGoogle Scholar
- 3.Wiltshaw E (1985) Ovarian trials at the Royal Marsden Hospital. Cancer Treat Rev 12 (Suppl A) 67–71Google Scholar